Pfizer reported second-quarter results that surpassed Wall Street expectations, with adjusted earnings per share of 77 cents compared to the anticipated 68 cents, and revenue of $15.03 billion versus the expected $14.41 billion [1]. The company attributed its performance to robust sales from non-Covid products, particularly Eliquis, which generated $2.43 billion in sales, marking a 19% increase and exceeding analyst forecasts of $2.08 billion [1]. Padcev, a targeted cancer drug, also contributed to the sales growth, helping offset declining revenues from Pfizer's Covid vaccine and Paxlovid antiviral pill [1].
Pfizer revised its full-year revenue guidance, raising the lower end to $60.5 billion from $59.5 billion, while maintaining the upper end at $62.5 billion. This range is expected to be flat or slightly down compared to 2025's revenue of $62.6 billion [1]. The company also lowered its full-year revenue expectation for Covid products to $4 billion, down from the previous estimate of $5 billion [1]. Despite these adjustments, Pfizer reiterated its full-year adjusted profit outlook of $2.80 to $3 per share [1].
The pharmaceutical giant reported a net loss of $248 million, or 4 cents per share, for the quarter, a significant decline from net income of $2.91 billion, or 51 cents per share, in the same period last year [1]. Excluding restructuring charges and costs related to intangible assets, the adjusted earnings per share stood at 77 cents [1].
Pfizer announced the second phase of a multi-year cost-cutting initiative targeting $1.5 billion in savings through 2029, focusing on product portfolio enhancements, network structure changes, and operational efficiencies [1]. The first phase is on track to deliver $1.5 billion in savings by the end of 2027, and an additional $1 billion in savings from a separate program will be achieved from 2027 to 2029. This adds to the previously announced $5.7 billion in cost savings expected by the end of the year [1].
Looking ahead, Pfizer is investing in its pipeline, including a recent $10 billion acquisition of obesity biotech Metsera, to counteract declining Covid product sales and losses from older drugs. Investors are closely watching upcoming data releases, particularly those related to a combination regimen involving Pfizer's GLP-1 injection and an amylin asset [1].
CONCLUSION
Pfizer's strong Q2 performance, driven by Eliquis and other non-Covid drugs, has led to an improved revenue outlook and renewed focus on cost-cutting and pipeline investments. Despite a net loss for the quarter and reduced expectations for Covid product sales, the company remains committed to operational efficiencies and long-term growth. Market sentiment is positive, with investors anticipating key data releases and further developments in Pfizer's product portfolio.